<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01404117</url>
  </required_header>
  <id_info>
    <org_study_id>LAQ-MS-201</org_study_id>
    <nct_id>NCT01404117</nct_id>
  </id_info>
  <brief_title>A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study Assessing the Safety and Tolerability</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teva Branded Pharmaceutical Products R&amp;D, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Branded Pharmaceutical Products R&amp;D, Inc.</source>
  <brief_summary>
    <textblock>
      A multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled&#xD;
      study to assess the safety, tolerability and efficacy of two daily doses of oral laquinimod&#xD;
      (0.6mg or 1.2mg) in adjunct to glatiramer acetate (GA) or interferon-beta (IFN-B) in&#xD;
      relapsing remitting multiple sclerosis (RRMS) subjects&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Study is being redesigned&#xD;
  </why_stopped>
  <start_date>March 2012</start_date>
  <completion_date type="Anticipated">January 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and efficacy</measure>
    <time_frame>10 months</time_frame>
    <description>To assess the safety, tolerability and efficacy of laquinimod in RRMS</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerability</measure>
    <time_frame>10 months</time_frame>
    <description>To assess the safety, tolerability and efficacy of laquinimod in RRMS as compared to placebo, subjects treated with GA or an IFN-B preparation (Avonex®, Betaseron®/Betaferon®, Rebif® or Extavia®).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Relapsing Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Laquinimod 0.6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GA 20 mg/1mL or an IFN-B preparation + oral daily administration of laquinimod 0.6 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Laquinimod 1.2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GA 20 mg/1mL or an IFN-B preparation + oral daily administration of laquinimod 1.2 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GA or IFN + Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GA 20 mg/1mL or an IFN-B preparation + oral daily placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Laquinimod 0.6</intervention_name>
    <description>Laquinimod 0.6 capsule</description>
    <arm_group_label>Laquinimod 0.6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Laquinimod 1.2</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Laquinimod 1.2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Glatiramer Acetate or interferon-beta+ Placebo</intervention_name>
    <description>GA 20 mg/1mL or IFN-B (Avonex®, Betaseron®/Betaferon®, Rebif® or Extavia®) + oral daily placebo</description>
    <arm_group_label>GA or IFN + Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects must have a documented MS diagnosis as defined by the Revised McDonald&#xD;
             criteria [Ann Neurol 2011: 69:292-302], with a relapsing-remitting disease course.&#xD;
&#xD;
          2. Subjects must be ambulatory with an EDSS score of 1-5.5 (inclusive) at the baseline&#xD;
             visit.&#xD;
&#xD;
          3. Subjects must be relapse-free and in a stable neurological condition and free of&#xD;
             corticosteroid treatment [intravenous (IV), intramuscular (IM) and/or oral] 30 days&#xD;
             prior to screening (month -1).&#xD;
&#xD;
          4. Subjects must be treated with either Copaxone® or an IFN-B preparation (Avonex®,&#xD;
             Betaseron®/Betaferon®, Rebif® or Extavia®), at a stable dose for at least 6 months&#xD;
             prior to the screening visit (switching between IFN-B preparations during the 6 months&#xD;
             prior to screening is allowed; switching between any IFN-B preparation and GA, or vice&#xD;
             versa, is exclusionary).&#xD;
&#xD;
          5. Subjects must have had experienced at least one documented relapse in the 36 weeks&#xD;
             prior to randomization, with an incomplete recovery of the neurological functions as&#xD;
             compared to pre-relapse status.&#xD;
&#xD;
          6. Subjects must be between 18 and 55 years of age, inclusive.&#xD;
&#xD;
          7. Women of child-bearing potential must practice an acceptable method of birth control&#xD;
             [acceptable methods of birth control in this study include: surgical sterilization,&#xD;
             intrauterine devices, oral contraceptive, contraceptive patch, long-acting injectable&#xD;
             contraceptive or double-barrier method (condom or diaphragm with spermicide)].&#xD;
&#xD;
          8. Subjects must be able to sign and date a written informed consent prior to entering&#xD;
             the study.&#xD;
&#xD;
          9. Subjects must be willing and able to comply with the protocol requirements for the&#xD;
             duration of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. An onset of a relapse between Month -1 (Screening) and 0 (Baseline), unstable&#xD;
             neurological condition or any treatment with corticosteroids [intravenous (IV),&#xD;
             intramuscular (IM) and/or oral] or Adrenocorticotropic hormone.&#xD;
&#xD;
          2. Use of experimental or investigational drugs, and/or participation in drug clinical&#xD;
             studies within the 6 months prior to Screening.&#xD;
&#xD;
          3. Use of immunosuppressive including Mitoxantrone (Novantrone®) or cytotoxic agents&#xD;
             within 6 months prior to the screening visit.&#xD;
&#xD;
          4. Previous use of either of the following: natalizumab (Tysabri®), cladribine,&#xD;
             laquinimod, and fingolimod (Gilenya®).&#xD;
&#xD;
          5. Previous treatment with intravenous immunoglobulin (IVIG) within 2 months prior to&#xD;
             screening visit.&#xD;
&#xD;
          6. Systemic corticosteroid treatment of ≥30 consecutive days duration within 2 months&#xD;
             prior to screening visit.&#xD;
&#xD;
          7. Previous total body irradiation or total lymphoid irradiation.&#xD;
&#xD;
          8. Previous stem cell treatment, autologous bone marrow transplantation or allogenic bone&#xD;
             marrow transplantation.&#xD;
&#xD;
          9. Use of moderate/strong inhibitors of cytochrome P450 CYP3A4 within 2 weeks prior to&#xD;
             the screening visit.&#xD;
&#xD;
         10. Use of inducers of CYP3A4 within 2 weeks prior to the screening visit.&#xD;
&#xD;
         11. Use of amiodarone within 2 years prior to screening visit.&#xD;
&#xD;
         12. Pregnancy or breastfeeding.&#xD;
&#xD;
         13. A ≥3xULN serum elevation of either alanine transaminase (ALT) or aspartate&#xD;
             transaminase (AST) at screening.&#xD;
&#xD;
         14. Serum direct bilirubin which is ≥2x upper limit of normal (ULN) at screening.&#xD;
&#xD;
         15. Subjects with a potentially clinically significant or unstable medical or surgical&#xD;
             condition that would preclude safe and complete study participation, as determined by&#xD;
             medical history, physical examinations, ECG, laboratory tests or chest X-ray. Such&#xD;
             conditions may include (but are not limited to):&#xD;
&#xD;
               -  A cardiovascular or pulmonary disorder that cannot be well-controlled by standard&#xD;
                  treatment permitted by the study protocol.&#xD;
&#xD;
               -  A gastrointestinal disorder that may affect the absorption of study medication.&#xD;
&#xD;
               -  Renal or metabolic diseases&#xD;
&#xD;
               -  Any form of acute or chronic liver disease&#xD;
&#xD;
               -  Known human immunodeficiency virus (HIV) positive status&#xD;
&#xD;
               -  A history of drug and/or alcohol abuse&#xD;
&#xD;
               -  An unstable psychiatric disorder.&#xD;
&#xD;
               -  A known history of tuberculosis.&#xD;
&#xD;
               -  Unstable psychiatric disorder&#xD;
&#xD;
               -  Any malignancies, excluding basal cell carcinoma (BCC), in the last 5 years.&#xD;
&#xD;
         16. A glomerular filtration rate less than 60 ml/min at screening visit.&#xD;
&#xD;
         17. A known history of sensitivity to gadolinium (Gd).&#xD;
&#xD;
         18. Inability to successfully undergo MRI scanning.&#xD;
&#xD;
         19. Previous endovascular treatment for Chronic Cerebrospinal Venous Insufficiency&#xD;
             (CCSVI).&#xD;
&#xD;
         20. Known drug hypersensitivity that would preclude administration of laquinimod, such as&#xD;
             hypersensitivity to: mannitol, meglumine or sodium stearyl fumarate.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ralf Gold, MD</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <verification_date>August 2013</verification_date>
  <study_first_submitted>July 26, 2011</study_first_submitted>
  <study_first_submitted_qc>July 26, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 27, 2011</study_first_posted>
  <last_update_submitted>August 26, 2013</last_update_submitted>
  <last_update_submitted_qc>August 26, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 27, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-beta</mesh_term>
    <mesh_term>Glatiramer Acetate</mesh_term>
    <mesh_term>(T,G)-A-L</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

